Centogene N.V. (NASDAQ:CNTG) Q2 2020 Earnings Conference Call - Final Transcript

Sep 23, 2020 • 08:00 am ET

Previous

Centogene N.V. (NASDAQ:CNTG) Q2 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Sun Kim

Thank you. Hello and welcome. Thank you for joining us to discuss our H1 2020 results, which were issued earlier today. You can view this presentation and the related press release on CENTOGENE's website. For those not able to view the webcast, you can find the relevant slides on www.investors.centogene.com.

Our speakers today are CENTOGENE's Chief Executive Officer, Prof. Arndt Rolfs; and Richard Stoffelen, CENTOGENE's Chief Financial Officer.

Before we begin, please refer to Slide 2 of our presentation, which provides information about certain statements to be made today that may be considered forward-looking statements within the meaning of the US securities laws, including those regarding our strategic plans, development programs, and future financial results. Statements made during this call that are not historical statements may be forward-looking statements and as such maybe subject to risks and uncertainties, which if they materialize could materially affect our actual results. The forward-looking statements in this presentation speak only as of today and we undertake no obligation to update or revise any of these statements to reflect future events or developments, except as required by the law. Additional information regarding these statements appears in our SEC filings.

Following our presentation, we will also open up the call to Q&A. We kindly ask that you ask only a maximum of three questions.

I will now hand the presentation over to Arndt. Please turn to Slide 3.

Executive
Prof. Arndt Rolfs

Thank you, Sun, and hello everyone. Thank you for joining our call today especially during this -- these unprecedented times. We hope everyone is staying healthy and safe, and our thoughts are with those affected by the COVID-19 pandemic.

Today, I will first walk through our operational performance during the first half of the year with more focus on Q2 as we already discussed Q1 performance in June. In addition to the progress of our core business, I will provide an update on our COVID-19 testing activities in recent months. Richard will then walk you through the financials and provide our view on how we see the rest of the year. Afterwards, we will open up the call for Q&A. I will remind you of Sun's request for everyone to only ask two or three questions, so that we have enough time to address as many questions as possible.

Let's please turn to Slide 4. Before we get into the performance each quarter, we always start our presentation with CENTOGENE's goal. I think it is always good to put things into context and for me that means, looking at recent achievements with our long-term goal in mind. Our ultimate goal is to provide precise medical diagnosis of inherited rare diseases at the earliest possible moment by transforming medical expertise and analytical information into actionable results for physicians, patients and pharmaceutical partners. Importantly over the last few months, we have been able to leverage that expertise to help address the COVID-19 pandemic. This is being driven by CENTOGENE doing its part in the fight against the unprecedented global challenge and